Racura Oncology LtdASX: RAC

Race Receives $5.25m RD Tax Refund for Financial Year 2024

· Issued by Racura Oncology Ltd

Filed with ASX · · 2 pages · English

Summary by 6ix AI

The company also received a positive determination regarding eligibility for overseas R&D activities, which extends the tax rebate to eligible activities conducted outside Australia. CEO Dr. Daniel Tillett emphasized the importance of this incentive for biopharmaceutical companies in addressing unmet patient needs and advancing clinical development.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Racura Oncology Ltd on 6ix

Earlier from Racura Oncology

Later from Racura Oncology

All Racura Oncology news releases